HAWK Biosystems Partners With Mayo Clinic on Lung Cancer Test

The collaboration will evaluate HAWK's QF-Pro platform for PD-1/PD-L1 testing in non-small cell lung cancer.

Updated on Nov. 19, 2026 in Cancer

Close view of a glass slide holding a pale pink tissue section on a steel laboratory bench, with a blurred automated instrument behind it.
HAWK Biosystems and Mayo Clinic will evaluate HAWK's QF-Pro PD-1/PD-L1 test in up to 100 non-small cell lung cancer tissue samples. AI Illustration. Upload story photo >

HAWK Biosystems, a precision diagnostics company based in Derio, Spain, announced a collaboration with Mayo Clinic to evaluate its QF-Pro PD-1/PD-L1 Quantification Kit in non-small cell lung cancer (NSCLC). Mayo Clinic will supply up to 100 formalin-fixed, paraffin-embedded tissue samples from confirmed NSCLC cases.

Why it matters

PD-L1 immunohistochemistry is the current standard for testing eligibility for checkpoint-inhibitor treatment in NSCLC, so a new quantification method could influence how that testing is performed. The collaboration is aimed at validating the platform before any broader clinical use.

The collaboration will draw on up to 100 confirmed NSCLC tissue samples, following a 2023 independent validation of the platform in a 237-patient cohort. Results from the new work have not yet been released.

The players

HAWK Biosystems

A precision diagnostics company headquartered at the Parque Tecnológico de Bizkaia in Derio, Spain, and backed by the investment firm Inveready.

Mayo Clinic

A nonprofit academic medical center in the United States that supplies the clinical tissue samples and medical expertise for the collaboration, and which has a financial interest in the technology.

The details

Mayo Clinic will use its own instrumentation and HAWK-provided reagents to develop an automated staining process for the samples. The stained samples will then be tested on HAWK's VIOLET 3.0 platform running QF-Pro software, and Mayo Clinic will provide de-identified clinical data and medical expertise under the agreement.

Timeline

  1. 2023: A prior independent clinical validation of the QF-Pro platform was published in the Journal of Clinical Oncology.

  2. November 19, 2026: HAWK Biosystems announced the collaboration with Mayo Clinic.

Health Landscape

The effort tests whether an automated PD-1/PD-L1 quantification platform can match the established PD-L1 immunohistochemistry used to guide checkpoint-inhibitor therapy in non-small cell lung cancer. Its outcome will show whether automated quantification can gain a place in that diagnostic pathway.

For people with non-small cell lung cancer, PD-L1 testing determines eligibility for certain immunotherapy treatments, so any change to how the test is run could affect treatment decisions. The collaboration is still in an evaluation stage, and no change to current testing is announced.

The takeaway

Any new PD-L1 test must be validated against established methods before it can guide treatment, so readers should rely on their care team's current testing approach. Results from this collaboration will need independent review before they change clinical practice.

Further reading

For background on how these tests are used in treatment decisions, see the Cancer section.

Source note: This article includes information reported by Biotech-spain.